hesperidin
Phase 2- Indications
- COVID-19
Company intelligence / Profile preview
Ingenew Pharma
Evanston, Illinois, United Statesingenewpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed a Phase 2 double-blind placebo-controlled clinical trial for hesperidin therapy in COVID-19 patients, showing a statistically significant reduction of 14.5% of Group A symptoms from 50.9% to 36.4% (p = 0.03)[5]
- Therapeutic areas
- OncologyDermatologyNeurologyInfectious Diseases
- Modalities
- Small molecules (hesperidin)proprietary formulationsdrug delivery systems
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Montreal Health Innovations Coordinating Center (MHICC)Ortho (license agreement for drug delivery systems)
Beyond the preview
Go deeper on Ingenew Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ingenew Pharma.